ELVN (Enliven Therapeutics, Inc.) Stock Financials & Earnings

ELVNEnliven Therapeutics, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$104M

EPS (TTM)-$1.83

Free Cash Flow (TTM)-$70M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q1 2026 · Mar 12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$16M
Q2 23	$0	$0	-$20M
Q3 23	$0	$0	-$24M
Q4 23	$0	$0	-$23M
Q1 24	$0	$0	-$26M
Q2 24	$0	$0	-$25M
Q3 24	$0	$0	-$27M
Q4 24	$0	$0	-$27M
Q1 25	$0	$0	-$32M
Q2 25	$0	$0	-$29M
Q3 25	$0	$0	-$25M
Q4 25	$0	-$46K	-$34M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$292M	$0	$292M
Q2 23	$126M	$152M	$278M
Q3 23	$74M	$190M	$263M
Q4 23	$100M	$153M	$253M
Q1 24	$149M	$171M	$321M
Q2 24	$97M	$216M	$312M
Q3 24	$101M	$191M	$292M
Q4 24	$124M	$189M	$313M
Q1 25	$102M	$188M	$290M
Q2 25	$119M	$371M	$491M
Q3 25	$102M	$376M	$478M
Q4 25	$99M	$364M	$463M

Shares Outstanding

Revenue Per Employee

Revenue / Employee